Influenza vaccine
AssigneeModernaTX, Inc.
InventorGiuseppe Ciaramella
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Claims11
A method of inducing an influenza virus antigen-specific immune response in a human subject, the method comprising administering by intramuscular injection to the human subject a composition comprising 10-100 μg of a messenger ribonucleic acid (mRNA) polynucleotide to thereby induce a protective antigen-specific immune response in the subject, wherein the mRNA polynucleotide comprises an open reading frame encoding an influenza virus hemagglutinin (HA) antigen and is formulated in a lipid nanoparticle (LNP), wherein 100% of uracil nucleosides in the open reading frame are N1-methylpseudouridine, and wherein the LNP comprises a cationic lipid of Formula (I):
- or a salt or isomer thereof, wherein:
- R1 is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, and —R″M′R′;
- R2 and R3 are independently selected from the group consisting of C1-14 alkyl and C2-14 alkenyl;
- R4 is —(CH2)nQ, where Q is —OR, and n is independently selected from 1, 2, 3, 4, and 5;
- each R5 is H;
- each R6 is H;
- M and M′ are independently selected from —C(O)O— and —OC(O)—;
- R7 is H;
- R is H;
- R′ is H;
- R″ is selected from the group consisting of C3-14 alkyl and C3-14 alkenyl;
- and
- m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.
Dependencies are inferred from the claim text.